CooperCompanies stock sank after its fiscal third-quarter report because investors looked past a modest adjusted-earnings beat and focused on slower sales, a deliberate reduction in U.S. contact-lens inventory, and a weak near-term outlook. The company generated record free cash flow and expanded its buyback authorization, but those positives did not resolve the central concern: CooperVision, its largest segment, is not currently growing.

The short answer is that the quality of the quarter was weaker than the headline profit figures suggested. CooperCompanies reported $1.066 billion of revenue, up only 1% year over year and roughly $30 million below the market forecast cited in independent earnings coverage. Adjusted diluted earnings per share reached $1.15, up 4% and slightly ahead of expectations, but revenue and guidance carried more weight than the beat.

Shares had already fallen 6.2% during regular trading on September 9 and then dropped about 16% after hours. The reaction was not simply a punishment for one missed estimate. It reflected a reset in expectations for the contact-lens business and skepticism that capital returns can substitute for organic growth.

CooperVision matters because it produced about two-thirds of company revenue in the quarter. Its $717 million of sales were essentially unchanged from a year earlier. The Americas declined 2%, while Asia-Pacific fell 5% in constant currency. Toric and multifocal lenses grew 2%, but sphere and other products declined 1% organically.

Management said it intentionally reduced inventory in the U.S. channel and expects the effect to continue into the fourth quarter. Destocking can be temporary: distributors may sell existing inventory before placing new orders, causing reported manufacturer sales to trail end-user demand. The risk is that investors cannot yet cleanly separate that timing effect from market-share pressure, product-mix weakness or softer underlying demand.

The next thesis test is therefore not whether Q4 looks weak—the guidance already anticipates that. It is whether order growth improves after channel inventory reaches a healthier level. A credible recovery would show stronger sell-through, stable customer retention and a return to positive CooperVision organic growth without aggressive discounting.

GAAP diluted EPS jumped to $2.24 from $0.49, but that comparison was dominated by a $307.2 million tax benefit tied to the favorable completion of a U.K. tax examination. Adjusted EPS of $1.15 provides a cleaner view of recurring operations, and it increased only 4%. That was respectable, but not strong enough to offset the top-line disappointment.

Margins were mixed. Reported gross margin improved to 67% from 65% because the prior-year period included inventory write-offs. On a non-GAAP basis, gross margin remained 67% but declined 60 basis points due to higher manufacturing costs and unfavorable foreign exchange. Non-GAAP operating margin rose 30 basis points to 26%, showing that expense discipline is helping even as revenue growth slows.

The strongest part of the report was cash generation. Free cash flow rose 66% to $273 million. CooperCompanies repurchased $339.1 million of stock during the quarter, buying roughly 4.9 million shares at an average price of $69.16. The board also increased the total authorization from $2 billion to $3 billion, leaving about $1.5 billion available.

Repurchases below a company’s estimate of intrinsic value can improve per-share economics, especially when cash flow is durable. But buybacks are not an operating catalyst by themselves. If the contact-lens business keeps losing momentum, purchasing shares will shrink the denominator without fixing the numerator. Investors should judge the program alongside debt, reinvestment needs and the post-destocking growth rate.

The board evaluated a sale of CooperSurgical but unanimously concluded that retaining the business was more attractive than the offers received. Management cited a valuation disconnect affected by a competitive update in the non-hormonal IUD market and a recent fertility-litigation settlement. CooperSurgical remains the faster-growing segment, with 3% organic growth in Q3 and 5% organic growth in fertility.

Keeping the unit preserves exposure to fertility and women’s health, while also leaving investors with a more complex two-business story. The decision raises the execution bar: management now needs to prove that ownership creates more value than separation would have, not merely that bids were disappointing.

Management expects fiscal Q4 revenue of $1.057 billion to $1.080 billion and adjusted EPS of $1.05 to $1.09. The segment outlook is more revealing: CooperVision organic revenue is expected to range from a 2% decline to flat, while CooperSurgical is projected to grow 4% to 6% organically. For the full year, total revenue guidance is $4.229 billion to $4.252 billion, with adjusted EPS of $4.51 to $4.55.

That outlook implies the inventory reset will remain a drag through year-end. It also means the fastest path to a better stock narrative is evidence that CooperVision can exit the reset with sustainable growth, rather than another increase in repurchase capacity.

CooperCompanies’ quarter was not a collapse in profitability; it was a warning about growth quality. Record cash flow, higher adjusted EPS and a larger buyback program give management financial flexibility. Yet the market is correctly focused on the larger question: when will CooperVision grow again? Until the inventory reset ends and underlying demand becomes easier to verify, COO is likely to trade on evidence of operational recovery rather than on the size of its repurchase authorization.